6th October 2026: Public PhD defence of Asme Binte Aziz Hepatitis E vaccination in Bangladesh: Evaluating Immunogenicity and Potential Risks for Pregnancy Outcomes from a Cluster-Randomized Trial

Asme Binte Aziz
Asme Binte Aziz

Congratulations to Asma Binte Aziz, MD, for successfully defending her thesis at Institute for Clinical Medicine, Dep. Microbiology, University of Oslo 7th October 2026 !

The public defence took place at Oslo University Hospital, Rikshospitalet, with opponents Professor Oana Sandulescu from Carol Davila University in Bucharest and Professor Rebecca Cox from University of Bergen.

Aziz was enrolled in the PhD programme at University of Oslo with Susanne Dudman as principal supervisor and co-supervisors dr. Zaman and assoc. prof. Torbjørn Wisløff.

ClinVir joins the new EU-project ONWARD: Together we move forward!

Susanne Dudman
Susanne Dudman

This project aims to combat the most common cause of acute viral hepatitis, zoonotic hepatitis E, in a One Health perspective. More than 30 European countries participate with a total of 150 members joining.
Susanne Dudman is representing Norway and is leading work group 2, focusing on clinical management. The group aims to establish robust and comparable clinical trial frameworks, standardize outcome measurements, and support the identification and development of antiviral therapies.

HEV vaccine trial results published in Lancet

Susanne G. Dudman
Susanne G. Dudman

Hepatitis E virus (HEV) infection is prevalent around the world, especially affecting low-income countries in Asia and Africa. High morbidity and mortality have been reported in pregnant women and their children. The only licensed vaccine against HEV, the recombinant HEV239, has been used in a large RCT in Bangladesh. The results from the clinical trial were published in Lancet recently. Senior author is Susanne G. Dudman, head of the The Clinical Virology Research Group group at the Department of Microbiology.

14th December 2023: Public PhD defence of Joakim Øverbø Hepatitis E Virus Epidemiology and Vaccine Response: Studies from Norway and Bangladesh

Joakim Øverbø
Joakim Øverbø

Congratulations to Joakim Øverbø at his public PhD defense which took place 14th December 2023 at the University of Oslo! 

He was enrolled in the PhD programme at the Institute of Clinical Medicine at Faculty of Medicine, University of Oslo with main supervisor Susanne Dudman as part of a project funded by Norwegian Research Council with co-supervisors Kathrine Stene-Johansen and Torbjørn Wisløff at Norwegian Institute of Public Health.

12th December 2023: Public PhD defence of Sara Debes Burdens of viral respiratory infection and consumption of antibiotics in Østfold, Norway

Sara Debes
Sara Debes

Congratulations to Sara Debes at her public PhD defense which took place 12th December 2023 at the University of Oslo! 

She was enrolled in the PhD programme at the Institute of Clinical Medicine at Faculty of Medicine, University of Oslo with main supervisor Susanne Dudman as part of a collaboration project with co-supervisors Christine Jonassen and Jon Birger Haug at Sykehuset Østfold and Birgitte de Blasio at Norwegian Institute of Public Health.

18th May 2023: Public PhD defence of Beatrice Pennati SARS-CoV-2 diagnosis in Covid-19 patients

Congratulations to Beatrice Pennati at her public PhD defense which took place 18th May 2023 at the University of Genova !
 
Beatrice has been researching SARS-CoV-2 diagnosis in Covid-19 patients during her project period in Italy. She also investigated various laboratory methods by the use of SARS-CoV-2 polymerase chain reaction test. The performace of various extraction-free methods were compared with the traditional extraction-based SARS-CoV-2 RT-PCR showing that the unheated extraction-free RT-PCR worked just as well as the standard. At Oslo University Hospital, Department of Microbiology, she examined the effect of Drug X against SARS-CoV-2 by using virus cell cultures. Further, results showed that for the 13,5% of faeces samples, it was possible to revive SARS-CoV-2 viable virions using the Vero-E6 cell line. 
Scroll to top